A difícil arte de "deslizar sobre o mundo" ou Montaigne, um político discreto ("De poupar a própria vontade" - III, 10)

De 1581 a 1585, Montaigne foi prefeito de Bordeaux. Foi acusado por detratores de não se ter aplicado o bastante e de não ter feito nada de marcante durante seus dois mandatos. Ao responder às acusações no ensaio "De poupar a própria vontade" (III, 10), o autor encontra a ocasião para uma crítica das paixões em geral e, em particular, das que pertencem ao contexto político. Isto porque ele visava, com sua aparente falta de aplicação aos deveres de prefeito, evitar a paixão que tantas vezes se oculta por trás do engajamento - a ambição, desejo de honras, glória, renome. Sobretudo, esperava evitar um duplo perigo, ao mesmo tempo ético e político: comprometer a própria liberdade numa busca servil da glória e subordinar o bem coletivo ao interesse pessoal. No presente estudo, procuraremos reconstituir a trama argumentativa do ensaio em questão, acompanhando de perto os argumentos que sustentam a crítica montaigniana das paixões, bem como a terapia muito particular a que o ensaísta as submete, a qual lhe permite fazer do episódio da Mairie de Bordeaux um modelo de conciliação entre o cuidado de si e o cumprimento dos deveres políticos.

Concomitant Cisplatin and Hyperfractionated Radiotherapy in Locally Advanced Head and Neck Cancer: 10-Year Follow-up of a Randomized Phase III Trial (SAKK 10/94)

To compare the long-term outcome of treatment with concomitant cisplatin and hyperfractionated radiotherapy versus treatment with hyperfractionated radiotherapy alone in patients with locally advanced head and neck cancer.

Predictors of severe late radiotherapy-related toxicity after hyperfractionated radiotherapy with or without concomitant cisplatin in locally advanced head and neck cancer. Secondary retrospective analysis of a randomized phase III trial (SAKK 10/94)

This secondary analysis was performed to identify predictive factors for severe late radiotherapy (RT)-related toxicity after treatment with hyperfractionated RT +/- concomitant cisplatin in locally advanced head and neck cancer.

Physical examination during chemoradiation predicts outcome of locally advanced head and neck cancer. Secondary results of a randomized phase III trial (SAKK 10/94)

OBJECTIVES To analyze the prognostic value of clinical tumor response during chemoradiation for locally advanced head and neck cancer. PATIENTS AND METHODS The locoregional response at 50.4Gy was assessed by physical examination (PE) in patients treated within the randomized trial SAKK 10/94 using hyperfractionated radiotherapy (RT), median total dose 74.4Gy with or without cisplatin 20mg/m(2) chemotherapy on 5 consecutive days during weeks 1 and 5 or 6 of RT. Response was classified as a complete response (CR), complete response with uncertainty (Cru), partial response (PR), stable disease (SD), or progressive disease (PD). The primary endpoint was time to treatment failure (TTF) due to any cause. Secondary endpoints included locoregional-recurrence-free survival (LRRFS), distant metastasis-free survival (DMFS) and overall survival (OS). Univariate and multivariate Cox proportional hazards (PH) models were applied to analyze the associations between survival endpoints and clinical tumor response. RESULTS A total of 136, 131 and 97 patients were evaluable for response at the primary tumor, lymph nodes and both sites combined, respectively. At 50.4Gy 57/136 (42%), 46/131 (35%) and 21/97 (22%) patients had a good response (CR/Cru vs. PR/SD) at the primary tumor, the lymph nodes, and both sites combined, respectively. The median follow-up times were 11.4, 9.6 and 11.4years for the three groups. Good responses were all significantly associated with improved TTF, LRRFS, DMFS and OS in univariate analysis whereas good response at the primary tumor and lymph nodes remained significantly associated with TTF and OS after multivariate Cox PH models. CONCLUSIONS Locoregional response at 50.4Gy was identified as predictor of oncologic outcome. PE during treatment should not be underestimated in clinical practice.